



## Measure 224: Melanoma: Overutilization of Imaging Studies in Melanoma

Reporting Option: Registry Only

Quality Domain: Efficiency and Cost Reduction

**Description:** Percentage of patients with a current diagnosis of Stage 0 through IIC melanoma or a history of melanoma of any stage, without signs or symptoms suggesting systemic spread, seen for an office visit during the one-year measurement period, for whom no diagnostic imaging studies were ordered.

**Instructions:** This measure is to be reported once per reporting period for patients with a current diagnosis of melanoma or a history of melanoma who are seen for an office visit during the reporting period. This measure is intended to reflect the quality of services provided for the primary management of patients with melanoma who have an office visit during the reporting period.

**There are two reporting criteria for this measure:**

**Option 1:** Patients with a diagnosis of Stage 0 through IIC melanoma without signs or symptoms suggesting systemic spread

**Submission of these measures is also required:**

**G8944** AJCC Melanoma Cancer Stage 0 through IIC Melanoma

**G8749** Absence of signs of melanoma (cough, dyspnea, tenderness, localized neurologic signs such as weakness, jaundice or any other sign suggesting systemic spread) or absence of symptoms of melanoma (pain, paresthesia, or any other symptom suggesting the possibility of systemic spread of melanoma)

**Option 2:** Patients with a history of any stage melanoma without signs or symptoms suggesting systemic spread

**Submission of this measure is also required:**

**G8749** Absence of signs of melanoma (cough, dyspnea, tenderness, localized neurologic signs such as weakness, jaundice or any other sign suggesting systemic spread) or absence of symptoms of melanoma (pain, paresthesia, or any other symptom suggesting the possibility of systemic spread of melanoma)

**Category II Codes:**

**3320F** None of the following diagnostic imaging studies ordered: CXR, CT, ultrasound, MRI, PET, and nuclear medicine scans;



Or

**3319F 1P** Documentation of medical reason(s) for ordering diagnostic imaging studies (e.g., patient has co-morbid condition that warrants imaging, other medical reasons);

Or

**3319F 3P** Documentation of system reason(s) for ordering diagnostic imaging studies (e.g., requirement for clinical trial enrollment, ordered by another provider, other system reasons)

Or

**G8750** Presence of signs of melanoma (cough, dyspnea, tenderness, localized neurologic signs such as weakness, jaundice or any other sign suggesting systemic spread) or presence of symptoms of melanoma (pain, paresthesia, or any other symptom suggesting the possibility of systemic spread of melanoma)

Or

**3319F** One of the following diagnostic imaging studies ordered: chest x-ray, CT, ultrasound, MRI, PET, or nuclear medicine scans

### CPT Codes:

99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215

**Note:** Eye codes (92002, 92004, 92012, 92014) are not included in this measure.

### Diagnosis Codes:

Diagnosis for melanoma: C43.0, C43.10, C43.11, C43.12, C43.20, C43.21, C43.22, C43.30, C43.31, C43.39, C43.4, C43.51, C43.52, C43.59, C43.60, C43.61, C43.62, C43.70, C43.71, C43.72, C43.8, C43.9, D03.0, D03.10, D03.11, D03.12, D03.20, D03.21, D03.22, D03.30, D03.39, D03.4, D03.51, D03.52, D03.59, D03.60, D03.61, D03.62, D03.70, D03.71, D03.72, D03.8, D03.9

**Clinical Recommendation Statements:** In asymptomatic patients with localized cutaneous melanoma of any thickness, baseline blood tests and imaging studies are generally not recommended and should only be performed as clinically indicated for suspicious signs and symptoms. Routine cross-sectional imaging (CT, PET, and MRI) is not recommended for patients with localized melanoma. For patients with stage IA melanoma, this is consistent with the National Institutes of Health guideline. For patients with stage IB to IIC, this recommendation is based on the very low yield of detection of subclinical disease. In patients with stage IIB-IIC, chest x-ray is optional. In any patient with localized melanoma, cross-sectional imaging should only be used to investigate specific signs or symptoms.